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Background. Nigeria was one of 3 polio-endemic countries before it was de-listed in September 2015 by the World Health Orga-
nization, following interruption of transmission of the poliovirus. During 2011–2014, Nigeria conducted serial polio seroprevalence sur-
veys (SPS) in KanoMetropolitan Area, comprising 8 local government areas (LGAs) in Kano that is considered very high risk (VHR) for
polio, to monitor performance of the polio eradication program and guide the program in the adoption of innovative strategies.
Methods. Study subjects who resided in any of the 8 local government areas of Kano Metropolitan Area and satisﬁed age criteria
were recruited from patients at Murtala Mohammed Specialist Hospital (Kano) for 3 seroprevalence surveys. The same methods were
used to conduct each survey.
Results. The 2011 study showed seroprevalence values of 81%, 75%, and 73% for poliovirus types 1, 2, and 3, respectively, among
infants aged 6–9months age. Among children aged 36–47months, seroprevalence values were greater (91%, 87%, and 85% for poliovirus
types 1, 2, and 3, respectively).
In 2013, the results showed that the seroprevalence was unexpectedly low among infants aged 6–9 months, remained high among
children aged 36–47 months, and increased minimally among children aged 5–9 years and those aged 10–14 years. The baseline sero-
prevalence among infants aged 6–9 months in 2014 was better than that in 2013.
Conclusions. The results from the polio seroprevalence surveys conducted in Kano Metropolitan Area in 2011, 2013, and 2014
served to assess the trends in immunity and program performance, as well as to guide the program, leading to various interventions
being implemented with good effect, as evidenced by the reduction of poliovirus circulation in Kano.
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In 1988, the World Health Assembly resolved to eradicate
poliomyelitis by 2000 [1]. Subsequently, the Global Polio Eradi-
cation Initiative (GPEI) was able to reduce the number of polio-
endemic countries and wild poliovirus (WPV) cases from 125
and 350 000, respectively, in 1988 to 3 and 416, respectively, by
2013 [2]. Indigenous transmission of WPV types 2 and 3 (WPV2
and WPV3) has since been interrupted globally [3, 4].
Nigeria was one of 3 remaining polio-endemic countries in
the world, alongside Afghanistan and Pakistan [5], but on 25
September 2015, following the historical interruption of trans-
mission of WPV for 14 months, theWorld Health Organization
(WHO) director general, Dr Margaret Chan, on behalf of the
WHO, delisted Nigeria as a polio-endemic country after 17
years of the country’s polio eradication effort.
However, until 2012, Nigeria was the only country with
transmission of all 3 poliovirus serotypes: WPV1, WPV3, and
circulating vaccine-derived poliovirus type 2 (cVDPV2) [6],
despite the conduct of multiple supplementary immunization
activities (SIAs) and the use of more-immunogenic polio vac-
cines [7]. This indicated a substantial immunity gap, which
led the country to determine how well children were protected
against polio and where the remaining gaps driving persistent
transmission were.
Based on the recommendations in the GPEI 2010–2012 stra-
tegic plan [8] on the conduct of polio seroprevalence surveys
(SPS), the Nigerian government, with GPEI partners, decided
to implement polio SPS in the high-risk states of the country.
The objective was to estimate the level of population immunity,
measure the programmatic progress through repeat surveys, and
provide valuable insight for development of innovative strate-
gies to interrupt poliovirus transmission.
Kano State has long been considered the epicenter of polio
transmission in Nigeria and as one of the world’s poliovirus
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sanctuaries [9, 10]. The state continues to be at high risk, such
that even with substantial reduction in the recorded number of
polio cases in Nigeria in 2014, it accounted for 5 of 6 WPV1
cases and 10 of 30 cVDPV2 cases in the country. By the recent
joint WHO, Centers for Disease Control and Prevention
(CDC), and Global Goods classiﬁcation, 20 of the 38 local gov-
ernment areas (LGAs; 53%) at very high-risk (VHR) for polio
transmission are from Kano State. All 8 urban LGAs of Kano
Metropolitan Area (KMA)—Kano Municipal, Fagge, Nassara-
wa, Dala, Gwale, Tarauni, Ungogo, and Kumbotso—fall into
this category. Based on this, Kano State, particularly the KMA
(Figure 1), was the natural ﬁrst choice for the survey.
Previous work has been done to measure and report the se-
roprevalence of polio serotypes among different age groups.
Giwa et al reported that seroprevalence to poliovirus serotypes,
although higher than values found in previous studies done in
Nigeria, was lower than in the developed world [11]. This was
corroborated by Iliyasu et al, who submitted that seroprevalence
levels found in their survey, speciﬁc to Kano, were much lower
than in corresponding serosurveys in Egypt and India [12, 13]
and are insufﬁcient to interrupt poliovirus transmission [14].
We present results of serial health facility–based polio sero-
prevalence surveys conducted in the 8 urban LGAs of KMA in
Kano State, focusing on infants aged 6–9 months and compar-
ing their seroprevalence levels in 2011, 2013, and 2014 to show
how ﬁndings of these SPS have been used to review the polio
eradication program in Nigeria and to subsequently develop in-
novative strategies for polio eradication.
METHODS
The Study
We began the initial survey with site assessment visits to the poten-
tial institutions, meeting potential investigators and deciding on
participating institutions, the study team, and a feasible operation-
al plan. The protocol received approval from the institutional re-
view board of Aminu Kano Teaching Hospital (Kano) and the
WHO Ethical Review Committee (Geneva, Switzerland).
A health facility–based cross-sectional design was chosen for
operational ease, using the busy pediatric outpatient depart-
ment of Murtala Mohammed Specialist Hospital (Kano).
Study subjects fulﬁlling the 2 criteria of age and LGA of resi-
dence among those attending the pediatric outpatient depart-
ment of Murtala Mohammed Specialist Hospital were
recruited for the study after receiving care for the conditions
that led to their hospital visit. The research physician then
screened further for eligibility, obtained informed consent
from the parent (as well as assent from children aged 10–14
years), and administered a questionnaire. Finally, blood samples
were collected from the subjects. At the end of the survey, the
samples were shipped to the CDC laboratory (Atlanta, Geor-
gia), where neutralizing antibodies to the poliovirus serotypes
were assessed following a standard protocol [15]. Children
with detectable antibody levels at a ≥1:8 dilution were consid-
ered seropositive for that speciﬁc poliovirus serotype.
The studies were managed by combined teams of the WHO
(headquarters and country ofﬁce), the Kano State Ministry of
Health, Aminu Kano Teaching Hospital, and the National
Primary Health Care Development Agency.
Dissemination of Results and Identiﬁcation of Interventions
The results from these SPS were compiled and disseminated to the
country’s National Polio Emergency Operations Center and to
the Expert Review Committee for Polio Eradication and Routine
Immunization (ERC) for consideration and recommendations.
At the 24th ERC meeting, in 2012, following review of the
results of the ﬁrst Kano SPS of 2011, a recommendation was
made to extend the SPS to other high-risk states, as well as to
other age groups [16]. This led to the 2013/2014 SPS in
Sokoto and Kebbi states and the repeat survey in Kano in
2013, involving 4 age groups (6–9 months, 36–47 months,
5–9 years, and 10–14 years), compared with the 2 age groups
(6–9 months and 36–47 months) in the 2011 Kano SPS.
Figure 1. A map of the study area, Kano Metropolitan Area, in Kano State, north-
ern Nigeria. Abbreviation: LGA, local government area.
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At the National Polio Emergency Operations Center, the
Emergency Operations Center Strategic Group, headed by the
WHO, reviewed the results, especially the low seropositivity re-
corded in infants aged 6–9 months, and various strategies were
adopted and prioritized for implementation.
Furthermore, to assess the impact of additional doses from
the various immunization plus days (IPDs) on the low immu-
nity proﬁle of this age group, a third SPS was conducted in Oc-
tober 2014 in Kano, this time in 2 age groups, 6–9 months and
19–22 months (ie, the children from the cohort aged 6–9
months at the time of the previous SPS, in 2013).
In 2014, for the ﬁrst time, all study participants were geocoded
and mapped, and the analysis subsequently conducted provided
valuable support to programmatic interventions. For example, Fig-
ure 4 shows the location of seronegative and zero-dose subjects at
the ward level within the LGAs. This geospatial analysis conﬁrmed
where there was a high density of zero-dose children during rou-
tine immunization (RI) activities and SIAs, as well as a high num-
ber of seronegative subjects. With these data, the program could
see where the gaps in vaccination coverage were and, in turn,
where there was a need to further review ongoing strategies.
To improve the program, some speciﬁc strategies were adopt-
ed and implemented, while some were scaled up. With respect
to SIAs, accelerated inactivated polio vaccine (IPV) introduc-
tion in campaigns was started in Kano in December 2014,
with enumeration of residents in targeted areas before im-
plementation. Also health camps, which had earlier been
suspended for security reasons, were reintroduced, and com-
bined vaccination with oral polio vaccine (OPV) and IPV in
KMA LGAs in Kano was conducted in the March 2015 IPDs.
All children aged 0–59 months received OPV, and children
aged 3–59 months also received an IPV dose.
The directly observed OPV (DOPV) strategy was scaled up to
include KMA LGAs. This strategy was instituted to ensure vac-
cination of children in noncompliant households and other
homes where children were being ﬁnger-marked by youths or
mothers before vaccination teams arrived, as well as households
in which vaccination teams colluded with mothers to ﬁnger-
mark children without vaccination. Furthermore, monitoring
through lot quality assurance surveys (LQAS) was modiﬁed
to estimate the number of OPV doses received by children
aged <5 years.
The RI intensiﬁcation project was established in February
2015 in LGAs with cVDPV2 and low population immunity,
and IPV was introduced into the RI schedule. In addition, the
2014 SPS ﬁndings were used as a high-powered advocacy tool to
encourage buy-in by the Kano State government into the new
strategies that had hitherto been conducted in other parts of
the state but had been resisted in KMA.
RESULTS
The polio SPS in 2011 revealed poliovirus seroprevalence values
in the group aged 6–9 months to be 81%, 75%, and 73% for
poliovirus types 1, 2, and 3, respectively, with higher values
Figure 2. Poliovirus seroprevalence among children, by age group, in Kano, Nigeria, during 2013.
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(91%, 87%, and 85%, respectively) in the group aged 36–47
months.
Seropositivity in the 2013 SPS, which was conducted in 4 age
groups, was low among infants aged 6–9 months and high
among children aged 36–47 months, with slightly greater fre-
quencies of seropositivity among children aged 5–9 years and
those aged 10–14 years (Figure 2). Among the children aged
6–9 months, the seroprevalence was 58% (95% conﬁdence in-
terval [CI], 51%–66%) to serotype 1, 42% (95% CI, 34%–
50%) to serotype 2, and 52% (95% CI, 44%–60%) to serotype
3, whereas among children aged 36–47 months, the seropreva-
lence was 93% (95% CI, 88%–96%) to serotype 1, 85% (95% CI,
78%–90%) to serotype 2, and 87% (95% CI, 81%–92%) to sero-
type 3. The seroprevalence levels increased only marginally in
the groups aged 5–9 years and 10–14 years.
Figure 3 shows a comparison of the seroprevalence for all 3
serotypes among infants aged 6–9 months. The highest levels
were in 2011 and for serotype 1. Seroprevalence for serotype
2 remained low across the 3 surveys, at <60%.
There was a positive correlation between the combined
number of RI and SIA OPV doses received and seroprevalence
levels for all serotypes in the group aged 6–9 months in 2014.
There was an increasing trend in seroprevalence levels for all se-
rotypes as the number of RI doses increased, with the highest
seroprevalence in children who received the greatest number
of doses and the lowest in those who received no immunization.
These differences in all groups were statistically signiﬁcant
(P < .0001). However, with the SIA doses, this correlation was
only true for serotypes 1 and 3 (Table 1) because SIA doses
were mostly of bivalent vaccine (bOPV).
Figure 3. Seroprevalence, by poliovirus serotype, among infants aged 6–9
months in Kano Metropolitan Area, Kano State, northern Nigeria, during 2011,
2013, and 2014.
Figure 4. Geographic information systems analysis of the distribution of individuals who received 0 or ≥1 dose of polio vaccine during routine immunization (RI) or supple-
mentary immunization activities (SIAs) in 2014, based on polio seroprevalence surveys. Abbreviation: LGA, local government area.
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Geographic information systems analyses in Figure 4 show
concentrated areas of zero-dose children from RI activities
and/or SIAs as revealed by the survey. These areas and the
high number of seronegative subjects indicate where the gaps
in immunization coverage are.
Dose proﬁling based on modiﬁcation of the December 2014
LQAS data was performed to indicate the proportion of chil-
dren aged 0–59 months and the subset aged 12–59 months
who had received ≥3 OPV doses since birth (Figure 5). Analysis
revealed that fewer children aged 0–59 months group had re-
ceived ≥3 OPV doses since birth, compared with the group aged
12–59 months, by the end of the December 2014 IPD round.
The RI intensiﬁcation project showed a 64% reduction in the
number of unimmunized children in 8 Kano LGAs where
cVDPV is circulating, compared with 58% among 36 Kano
LGAs where cVDPV is not circulating (Figure 6). There was
also a marked reduction in number of unimmunized children
overall, from approximately 43 000 during January–December
2013 to approximately 15 000 during January–December 2014.
DISCUSSION
We found that the proportion of infants aged 6–9 months who
were seropositive to the 3 poliovirus serotypes remained consis-
tently low in the 3 facility-based polio SPS that were conducted
in KMA in the same health facility, thereby identifying a major
gap that contributed to the persistent poliovirus transmission in
Kano.
The marked drop in seroprevalence for all 3 serotypes in the
group aged 6–9 months between 2011 and 2013 brought into
focus the quality of IPD operations and the need to devise
new strategies to reach the younger children, especially newborn
babies and infants, most of whom would be with their mothers
and therefore be in the category of “child absent” during IPDs.
The evidence provided by the study yielded an increase in re-
sources for demand-creation activities targeting mothers and
caregivers of children in this age group.
An improvement in seroprevalence of 14% for type 1, 7% for
type 2, and 12% for type 3 was recorded in 2014, compared with
2013. We also found that the seroprevalence for serotype 2 was
low, at <60%, during the 3 surveys; seroprevalence was highest
in 2011 but decreased in 2013 and 2014.
Table 1. Seroprevalence of Poliovirus Among Infants Aged 6–9 Months, by Number of Oral Polio Vaccine (OPV) Doses Received—Kano State, Nigeria,
2014
Dose Type, No. Children, No.
Seroprevalence, No. (%)
PV1 P Value PV2 P Value PV3 P Value
RI OPV doses, no. <.001 <.001 <.001
0 41 18 (43.9) 11 (26.8) 13 (31.7)
1 13 9 (69.2) 6 (46.2) 10 (76.9)
2 18 16 (88.9) 11 (61.1) 13 (72.2)
3 20 14 (70.0) 13 (65.0) 13 (65.0)
4 89 74 (83.2) 66 (74.2) 68 (76.4)
SIA OPV doses, no. .036 .705 .013
0 28 19 (67.9) 15 (53.6) 13 (46.4)
1–3 57 37 (64.9) 35 (61.4) 38 (66.7)
4–6 67 51 (76.1) 42 (62.7) 43 (64.2)
≥7 26 23 (88.5) 15 (57.7) 22 (84.6)
Total doses, no. <.001 .002 <.001
0 6 2 (33.3) 2 (33.3) 0 (0.0)
1–3 36 20 (55.6) 15 (41.7) 16 (44.4)
4–6 55 38 (69.1) 32 (58.2) 38 (69.1)
≥7 84 71 (84.5) 58 (69.1) 63 (75.0)
Abbreviations: PV1, poliovirus type 1; PV2, poliovirus type 2; PV3, poliovirus type 3; RI, routine immunization; SIA, supplementary immunization activity.
Figure 5. Modified data from a lot quality assurance survey of 213 local govern-
ment areas in December 2014, showing the percentages of children, by age group,
who had received ≥3 doses of oral polio vaccine since birth.
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We also observed a clear correlation between seroprevalence
and the number of OPV doses received by the study subjects, giv-
ing us evidence that the suboptimal seroprevalence we recorded
arose because children were not being reached with repeated
doses of OPV as required. Our ﬁndings were in agreement
with those of Giwa et al, who submitted that immunization
was the single most important determinant of seropositivity
to poliovirus serotypes [11].
In RI activities, there is an increase in seroprevalence for all
serotypes, since trivalent OPV (tOPV) is used. For SIAs, there is
correlation only with serotypes 1 and 3, owing to continuous
administration of bOPV during SIAs in Kano. This has provid-
ed evidence supporting the conduct of more SIAs, using tOPV.
Comparison of the combined doses from RI activities and SIAs
with seroprevalence data showed the trend clearly. This positive
correlation between the number of OPV doses and the preva-
lence (≥90%) of higher antibody titers among children who re-
ceived >7 OPV doses clearly addresses concerns about receipt of
too many OPV doses that are often expressed by health profes-
sionals and noncompliant parents [17].
The geospatial analyses, which were included in the 2014 SPS
for the ﬁrst time, proved to be a valuable tool because they val-
idated the ﬁndings of areas of high density of zero-dose children
during RI activities and/or SIAs, as well as the high number of
seronegative subjects. These ﬁndings encouraged the program
to target innovative strategies on the younger age group, to con-
duct more tOPV SIAs, and to remunerate IPD vaccination
teams and community informants with 1000 Nigerian naira
(US$5) for every conﬁrmed case of acute ﬂaccid paralysis
found. The directly observed OPV (DOPV) strategy was imple-
mented in very high-risk and very very high-risk areas (61 of
69), which included the KMA.
IPV has proved successful in protecting children in areas
where the prevalence of immunity is low, with an efﬁcacy of
>90%, as seen in studies conducted in Ivory Coast in 1993
[18]. Nigeria started using IPV in Borno, Yobe, and 12 LGAs
of Kano State beginning in December 2014, and IPV was intro-
duced in KMA LGAs as one of the strategies for improvement,
during the March 2015 IPDs. According to the Kano Emergen-
cy Operations Center Report, a total of 956 499 and 861 174
children were immunized with OPV and IPV. In February
2015, IPV was introduced into the routine immunization pro-
gram of Nigeria.
The dose proﬁling done using the LQAS data (Figure 5)
showed that fewer children aged 0–59 months received ≥3
OPV doses, compared with the group aged 12–59 months, dur-
ing the IPD round of December 2014. This difference is due to
the population aged <1 year, which is generally underimmu-
nized, as corroborated by results of our seroprevalence surveys
for KMA. Based on LQAS data from January 2015, the propor-
tions of 0-dose children and underimmunized children, by
LGA, were estimated and the location of 0-dose children among
those aged 0–35 months and 36–59 months were mapped for
prioritization.
The RI intensiﬁcation project in LGAs with cVDPV2 and
low population immunity, which was established to tackle the
persistently low seroprevalence to poliovirus type 2, resulted
in an 80% reduction of unimmunized children over 6 months
of implementation.
Our study was hospital based, but this limitation may have
resulted in an overestimation of seroprevalence of antibody
against poliovirus, as the children who are not reached by im-
munization activities may be less likely to visit hospitals. The
results, although not generalizable, have been sufﬁcient for
the program to deﬁne innovative strategies to reach more chil-
dren in targeted age groups, and this has contributed in the
interruption of WPV circulation in Kano and the country as
a whole.
The results of the serial SPS conducted in KMA, a very very
high-risk area of Kano City, have helped bring focus to the qual-
ity of SIAs and to develop new strategies targeting the group
aged 6–9 months, in which the seroprevalence was lowest.
Figure 6. Results from the routine immunization intensification project. Comparison of the numbers of unimmunized children in 8 local government areas (LGAs) with
circulating vaccine-derived poliovirus (cVDPV) and 36 LGAs without cVDPV in Kano State during January–December 2012 and January–December 2013.
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These innovative strategies have contributed to the reduction of
WPV transmission in Kano and elsewhere in the country. Ni-
geria has not recorded any WPV cases in the year, and the
country has since been delisted as a polio-endemic country,
having interrupted polio transmission! As we recommended,
another SPS was conducted in Kano in October 2015 to fully
appreciate the impact of all these interventions.
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